IDEAYA Biosciences price to sales ratio IDYA

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 14.3×
5-year median: 22.2×
Against its 5-year history: 11th; percentile: 0 is its lowest day, 100 its highest
5-year range: 12.5× to 200×
Peer median: 3.5×

IDEAYA Biosciences' price to sales ratio is 14.3× as of Oct 23, 2026.

That is below its 5-year median of 22.2×, lower than on 89% of days in the last 5 years.

Over that time it ranged from 12.5× in Sep 2022 to 200× in Jul 2024.

The median for 10 large drugmakers of a similar size is 3.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	14.3×	13.5×	16.5×
2025	184×	184×	184×
2024	196×	94.1×	200×
2023	97.7×	13.0×	97.7×
2022	17.5×	12.5×	23.0×
2021	25.6×	23.2×	29.0×

Against its peers

Companies in Drug Manufacturers - General nearest IDEAYA Biosciences' size, closest first, today.

Company	Price to sales ratio
IDYAIDEAYA Biosciences	14.3×
OGNOrganon	0.6×
LQDALiquidia	8.5×
ARQTArcutis Biotherapeutics	8.5×
NRIXNurix Therapeutics	3.9×
INDVIndivior Pharmaceuticals	3.1×
PBHPrestige Consumer Healthcare	2.0×
HRMYHarmony Biosciences	2.2×
KNSAKiniksa Pharmaceuticals International	7.1×
LGNDLigand Pharmaceuticals	20.8×
AMRXAmneal Pharmaceuticals	2.1×
Peer median	3.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on IDEAYA Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.